secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001193125-24-076613
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Therapeutics announces $24M registered direct offering of common stock and warrants
--------------------------------------------------------------------------------

- Offering includes 24.8M shares, 3.8M pre-funded warrants, and 28.6M purchase warrants at $0.84/unit.
- Gross proceeds expected ~$24.0M; closing on or about March 26, 2024.
- Placement agents: Barclays Capital Inc. and Cantor Fitzgerald & Co.; 6% cash fee.
- Pre-funded warrant exercise price $0.01; purchase warrant exercise price $1.00 with 5.5-year term.
- Lock-Up Agreements from directors and officers restrict share sales for a period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/0001193125-24-076613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-076613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer